Abstrak Keganasan hidung dan sinus paranasal (sinonasal) merupakan tumor yang jarang ditemukan, hanya merupakan 1% dari seluruh tumor ganas di tubuh dan 3 % dari keganasan di kepala dan leher. Diagnosis secara dini dan pengobatan sampai saat ini masih merupakan tantangan. Pasien dengan tumor sinonasal biasanya datang pada stadium yang sudah lanjut, dan umumnya sudah meluas ke jaringan sekitarnya. Tidak jarang keluhan utama pasien justru akibat perluasan tumor seperti keluhan mata dan kepala dan bahkan gejala akibat metastsis jauh. Prognosis keganasan ini umumnya buruk. Hal ini karena anatomi sinus yang merupakan rongga yang tersembunyi dalam tulang, yang tidak akan dapat dideteksi dengan pemeriksaan fisik biasa dan sering asimptomatik pada stadium dini serta lokasinya yang berhubungan erat dengan struktur vital. Dilaporkan satu kasus tumor sinus paranasal pada seorang lali-laki berusia 52 tahun yang telah mengalami perluasan ke intrakranial dan metastasis ke paru. Kata kunci: tumor sinonasal, perluasan intrakranial, metastasis paru. Abstract Malignancies of the nasal cavity and paranasal sinuses (sinonasal) are rare, comprising only 1 % of all human malignancies and only 3 % of those arising in the head and neck. Early diagnosis and treatment are still a challenge. A patient with sinonasal tumors usually comes at the advanced stage, and generally has spread to surrounding tissue. Not infrequently the patient's main complaint due to the expansion of the tumors such as eye or head complaints and sometimes even result of distant metastases. It has been associated with a poor prognosis. This is because the anatomy of the sinuses, which is a hidden cavity in the bone, which can not be detected by regular physical examination, tend to be asymptomatic at early stages, and located close anatomic proximity to vital structures. A case of paranasal sinus tumors in a 52-year-old man who has experienced intracranial expansion and pulmonary metastases is reported. Keywords: sinonasal tumor, intracranial expansion, pulmonary metastases.
Background: Meningiomas are common central nervous system neoplasms, accounts for 30% of all primary intracranial neoplasms; the occurrence of meningiomas with cystic lesions is an exceptionally rare. Lymphoplasmacyte-rich meningioma (LPRM) is a rare pathological entity belong to the World Health Organization Grade I meningiomas. LPRM is characterized by abundant lymphoplasmacytic infiltrates which over-shadow the underlying meningothelial component. Case Description: A 42-year-old male was admitted to our hospital with a chronic headache for about 3 weeks prior to admission. His symptoms worsen, and subsequently, he experienced left extremities weakness about 1 week before admission. His brain magnetic resonance imaging revealed an irregular and heterogeneously enhancing solid lesion with intratumoral cystic changes at the temporal lobe. A gross total resection was performed; pathological examination revealed a cystic LPRM. Conclusion: This rare variant of meningioma is a benign tumor entity featured with massive inflammatory cell infiltration and often less proportion of meningothelial elements. Surgical resection remains the treatment of choice. This is the first report regarding cystic LPRM from Indonesia; we also summarized relevant literature upto-date, May 2020, reported LPRM cases.
Background:Malignant peripheral nerve sheath tumors (MPNSTs) constitute a group of soft tissue neoplasm with neuroectodermal origin. Most cases are small at presentation and only some have been described reaching giant dimensions.Case Description:We report two cases that were diagnosed and treated as giant MPNST of the scalp. Both patients had extensive lesion on the head with intracranial infiltration. Microsurgical resection was indicated and a vascularized free flap was used to cover the defect. During follow-up the tumors recurred and further surgical excision treatment by adjuvant radiation therapy was performed.Conclusion:MPNSTs of the scalp are rare neoplasm of the peripheral nervous system. They are aggressive lesion that can recur and their management requires a multimodality approach.
BACKGROUND: Histopathological examination is the gold standard for diagnosing meningioma and determining the treatments. However, it is invasive in nature. This study was conducted to identify intratumoral and peritumoral apparent diffusion coefficient (ADC) value and mRNA O6-methylguanine-DNA methyltransferase (MGMT) expression in meningioma.METHODS: Data were collected from 39 patients who were clinically diagnosed with meningioma. However, only 37 patients met the inclusion criteria. These subjects then underwent examinations and received treatment from October 2017 to September 2018. Magnetic resonance imaging (MRI) data with diffusion-weighted imaging-apparent diffusion coefficient (DWI-ADC) sequence, histopathological diagnosis of meningioma, and results of MGMT mRNA expression were obtained.RESULTS: The most frequent type of low-grade and overall tumor was meningioma not otherwise specified (56.8%). For high-grade tumor, there were two atypical cases: atypical meningioma (2.7%) and rhabdoid meningioma (2.7%). Meningothelial meningioma had the highest mean value of minimum intratumoral ADC at 864.57±219 x10-3 mm2/s, whereas rhabdoid meningioma had the lowest at 417 x10-3 mm2/s. For minimum peritumoral ADC, rhabdoid meningioma had the highest mean value at 1,651 x10-3 mm2/s, while atypical meningioma has the lowest at 1,281 x10-3 mm2/s. For MGMT mRNA, meningothelial meningioma had the highest mean value at 10±1.2 fold change, whereas rhabdoid meningioma had the lowest mean at 6.18 fold change.CONCLUSION: WHO grade I meningiomas had higher minimum intratumoral ADC values and higher MGMT mRNA expression than the high-grade tumors. Minimum peritumoral ADC values differed across the histopathological grades.KEYWORDS: meningioma, RNA, messenger, MRI, methyltransferases, RT-PCR, ADC, MGMT mRNA
Introduction: Brain tumor is a neoplasm originating from various type of intracranial tissue. Histopathology is the gold standard to diagnose brain tumor. However, due to its invasive nature, the biopsy procedure poses a substantial risk. Therefore, advanced imaging, such as conventional Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS), has been widely developed to determine brain tumor type. Conventional MRI has been a routine examination for a suspected brain tumor in Indonesia, and with the utilization of MRS, could theoretically improve the diagnostic yield. This study aims to find diagnostic properties of conventional MRI, Choline/Creatine and Choline/NAA ratio extracted from MRS, and as a combined parameter to differentiate brain tumor type.Methods: This cross-sectional study involved 52 patients who underwent conventional MRI, MRS, and histopathology examination for a suspected brain tumor. The cut-off from Dean Criteria of conventional MRI, Choline/Creatine and Choline/NAA ratio to classify tumor type was determined from the ROC curve and then the diagnostic parameters were calculated from cross-tabulation. Also, a novel approach was made with logical-mathematical equation (disjunction/ Ë… / “or†and conjunction/ Ë„ / “andâ€) to combined parameter obtained from MRI and MRS to predict histopathological brain tumor type.Results: Conventional MRI combined with MRS improve diagnostic yield compared to a single parameter with a sensitivity of 87.5%, a specificity of 88.6%, accuracy of 88.5%, PPV of 58.3%, NPV of 97.5%, LR+ of 7.68, dan LR- of 0.1.Conclusion: Combination of conventional MRI and MRS parameter could improve the diagnostic yield in differentiating the type of brain tumor.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.